Introduction Filgrastim is a granulocyte colony-stimulating factor (GSCF) used in some chemotherapy regimen to prevent febrile neutropenia. Most common reaction of filgrastim are aches and pain including headaches, nausea and skin rash. Case report We report the case of a patient who developed unusual, non-commonly reported adverse toxidermy to filgrastim. At first the eruption was limited to the lower members and genetics organs. Then it slowly spread across the whole body presenting as a polymorphic exanthematous-pustulosis lesions. Management & Outcome A cutaneous biopsy was done, identifying a toxidermy modified by systemic treatment. A pharmacological study linked the role of filgrastim to these lesions. After switching from filgrastim to lénograstim, his lesions are completely gone and haven't flared up again. Thus, clearly imputing the use of filgrastim. Discussion The cutaneous reaction that has reported with use of GSCF are sweet syndrome, erythema nodosum, pyoderma nodosum and pyoderma gangrenosum. As far as we know, no acute generalized exanthematous pustulosis due to GSCF has been reported.
Introduction:CNS embryonal tumors are highly malignant undifferentiated or poorly differentiated tumors of neuroepithelial origin, they take origin from embryonic cells that remain in the brain after birth, These tumors tend to spread through the cerebrospinal fluid (CSF) to other parts of the brain and spinal cord.Central nervous system embryonal tumor, not otherwise specified (NOS) was previously called primitive neuroectodermal tumors (PNET), these are rare tumors that form in the brain and spinal cord. (1)We describe CNS (NOS) that arose in the occipital lobe of a 27 year old patient.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.